CT-388 is a dual
GLP-1 and
GIP receptor agonist.[1] In a 24-week trial participants averaged 18.8 percent placebo adjusted weight loss. The drug is developed by
Genentech.[2][3]
References
^Chakravarthy, Manu; ArgüElles-Tello, Federico A.; Sun, Ana Liza A.; Elliott, Michael; Acosta, Luis; Rankin, Jonathon E.; Hansen, Stig K. (20 June 2023). "75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults". Diabetes. 72 (Supplement_1).
doi:
10.2337/db23-75-LB.